Steven R. Miller is the Chief Operating Officer (COO) and Chief Scientific Officer (CSO) at Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare neurological and epileptic diseases. With a robust background in the pharmaceutical industry, Miller brings a wealth of experience and expertise to his leadership roles at Catalyst. Before joining Catalyst, he held various positions at major pharmaceutical companies, including Schering-Plough and Purdue Pharma, where he honed his skills in drug development, regulatory affairs, and strategic planning. In his current roles as COO and CSO at Catalyst Pharmaceuticals, Miller oversees the company's operational strategies and scientific initiatives. He plays a crucial role in guiding the development and commercialization of Catalyst's product portfolio, which includes treatments for Lambert-Eaton myasthenic syndrome (LEMS) and epilepsy. Under his leadership, the company has made significant progress in expanding its pipeline and strengthening its position in the rare disease market. Miller's strategic vision and scientific acumen have been instrumental in driving Catalyst's growth and success. Throughout his career, Steven R. Miller has demonstrated a strong commitment to advancing healthcare and improving patient outcomes. His contributions to the field have been recognized through various accolades and awards. At Catalyst, he continues to lead with integrity and innovation, fostering a culture of excellence and collaboration. As the company navigates the complex landscape of rare disease drug development, Miller's leadership and expertise remain vital to Catalyst's mission of transforming the lives of patients and their families.